By Steve Moore | Tuesday 17 May 2022
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
A “Trading Update - FY22 in line with expectations”-titled announcement from tissue converter group Accrol (ACRL) sounds good given the current macro climate. So what of a current 26p share price?...